IRIDEX Corporation (IRIX)

Currency in USD
1.410
+0.090(+6.82%)
Closed·
After Hours
1.420+0.010(+0.70%)
·
IRIX Scorecard
Full Analysis
Quickly burning through cash
Unusual trading volume
Fair Value
Day's Range
1.3901.590
52 wk Range
0.7822.140
Key Statistics
Prev. Close
1.32
Open
1.45
Day's Range
1.39-1.59
52 wk Range
0.782-2.14
Volume
379.81K
Average Volume (3m)
101.87K
1-Year Change
-31.22%
Book Value / Share
0.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IRIX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

IRIDEX Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

IRIDEX Corporation Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

IRIDEX Corporation Earnings Call Summary for Q4/2024

  • Q4 2024: Net loss of $800,000 ($0.05/share), revenue $12.7M. Stock surged 13.04% after hours to $0.998
  • Revenue up 2% YoY, 10% sequentially. Gross margin improved to 44% from 39.2% prior year
  • Achieved positive adjusted EBITDA for first time. Strategic investment from Novel Innovations enhances growth prospects
  • 2025 revenue expected similar to 2024. Company aims to remain adjusted EBITDA and cash flow positive
  • Special call planned mid-April to discuss evolving strategy before ASCRS meeting
Last Updated: 27/03/2025, 22:44
Read Full Transcript

Compare IRIX to Peers and Sector

Metrics to compare
IRIX
Peers
Sector
Relationship
P/E Ratio
−3.3x−3.9x−0.5x
PEG Ratio
−0.09−0.290.00
Price/Book
27.8x2.2x2.6x
Price / LTM Sales
0.5x3.4x3.2x
Upside (Analyst Target)
41.8%15.5%41.6%
Fair Value Upside
Unlock7.0%6.0%Unlock

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.10 / -0.10
Revenue / Forecast
11.90M / 12.10M
EPS Revisions
Last 90 days

IRIX Income Statement

People Also Watch

0.980
WINT
-3.92%
0.6427
OPTT
-14.83%
2.4400
KNW
-14.69%
5.0900
CLRB
-4.86%
1.910
MBIO
-5.91%

FAQ

What Stock Exchange Does IRIDEX Trade On?

IRIDEX is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for IRIDEX?

The stock symbol for IRIDEX is "IRIX."

What Is the IRIDEX Market Cap?

As of today, IRIDEX market cap is 23.67M.

What Is IRIDEX's Earnings Per Share (TTM)?

The IRIDEX EPS (TTM) is -0.43.

When Is the Next IRIDEX Earnings Date?

IRIDEX will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is IRIX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has IRIDEX Stock Split?

IRIDEX has split 0 times.

How Many Employees Does IRIDEX Have?

IRIDEX has 93 employees.

What is the current trading status of IRIDEX (IRIX)?

As of 28 Jul 2025, IRIDEX (IRIX) is trading at a price of 1.41, with a previous close of 1.32. The stock has fluctuated within a day range of 1.39 to 1.59, while its 52-week range spans from 0.78 to 2.14.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.